LinkedIn

 آمار

تعداد نشریات21
تعداد شماره‌ها1,292
تعداد مقالات11,793
تعداد مشاهده مقاله83,088,105
تعداد دریافت فایل اصل مقاله121,853,811
Shakeri, Mahsa, Amraee, Azadeh, Hosseini, Seyyed Mohammad, Darvish, Leili, Farkhondeh, Forough, Mostaar, Ahmad, Ghadiri, Hossein. (1405). PET-based Radiomics Analysis for Predicting Prognosis and Differentiation Treatment-Related Changes in Glioma: A Systematic Review. سامانه مدیریت نشریات علمی, 16(4), 267-284. doi: 10.31661/jbpe.v0i0.2409-1821
Mahsa Shakeri; Azadeh Amraee; Seyyed Mohammad Hosseini; Leili Darvish; Forough Farkhondeh; Ahmad Mostaar; Hossein Ghadiri. "PET-based Radiomics Analysis for Predicting Prognosis and Differentiation Treatment-Related Changes in Glioma: A Systematic Review". سامانه مدیریت نشریات علمی, 16, 4, 1405, 267-284. doi: 10.31661/jbpe.v0i0.2409-1821
Shakeri, Mahsa, Amraee, Azadeh, Hosseini, Seyyed Mohammad, Darvish, Leili, Farkhondeh, Forough, Mostaar, Ahmad, Ghadiri, Hossein. (1405). 'PET-based Radiomics Analysis for Predicting Prognosis and Differentiation Treatment-Related Changes in Glioma: A Systematic Review', سامانه مدیریت نشریات علمی, 16(4), pp. 267-284. doi: 10.31661/jbpe.v0i0.2409-1821
Shakeri, Mahsa, Amraee, Azadeh, Hosseini, Seyyed Mohammad, Darvish, Leili, Farkhondeh, Forough, Mostaar, Ahmad, Ghadiri, Hossein. PET-based Radiomics Analysis for Predicting Prognosis and Differentiation Treatment-Related Changes in Glioma: A Systematic Review. سامانه مدیریت نشریات علمی, 1405; 16(4): 267-284. doi: 10.31661/jbpe.v0i0.2409-1821

PET-based Radiomics Analysis for Predicting Prognosis and Differentiation Treatment-Related Changes in Glioma: A Systematic Review

Journal of Biomedical Physics and Engineering
مقاله 2، دوره 16، شماره 4 - شماره پیاپی 1، آبان 2026، صفحه 267-284    اصل مقاله (863.68 K)
نوع مقاله: Systematic Review
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.2409-1821
نویسندگان
Mahsa Shakeri1، 2؛ Azadeh Amraee3؛ Seyyed Mohammad Hosseini1، 2؛ Leili Darvish4، 5؛ Forough Farkhondeh6؛ Ahmad Mostaar7؛ Hossein Ghadiri* 1، 2
1Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2Research Center for Molecular and Cellular Imaging (RCMCI), Advanced Medical Technologies and Equipment Institute (AMTEI), Tehran University of Medical Sciences, Tehran, Iran
3Department of Medical Physics, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
4Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
5Department of Radiology, Faculty of ParaMedicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
6Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
7Department of Medical Physics and Biomedical Engineering, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
چکیده
Background: The assessment of treatment-induced changes in glioma and the evaluation of glioma prognosis are crucial components of effective treatment management. Radiomics models based on Positron Emission Tomography (PET) imaging can provide critical insights into therapeutic response monitoring.
Objective: This systematic review aimed to evaluate the performance of PET-based radiomics models in distinguishing treatment-related changes and predicting the prognosis of glioma.
Material and Methods: In this systematic review, the articles were searched from the Web of Science databases, MEDLINE, PubMed, and EMBASE. The search terms were “amino acid PET”, “PET”, “glioblastoma”, “glioma”, “positron emission tomography”, “machine learning”, “deep learning”, “radiomics”, “artificial intelligence”, “AI”, “prognosis”, “outcome”, “post treatment changes”, “treatment-related changes”, “progression”, “true progression” “pseudo-progression”, and “necrosis”. The titles, abstracts, and full text of the recognized citations were reviewed by two independent reviewers and then the selected articles were abstracted by two independent reviewers based on a standard grid. PRISMA checklist was applied to assess the overall quality of evidence for each outcome.
Results: The PET-based radiomics models outperform conventional PET parameter models, such as maximum tumor-to-brain ratios and mean tumor-to-brain ratios in distinguishing post-treatment changes and predicting glioma prognosis. The model integrating radiomics features and the conventional PET parameters achieved superior diagnostic performance compared to radiomics and conventional parameter models solely in differentiation treatment related changes. 
Conclusion: PET based radiomics models demonstrate enhanced capability in differentiating tumor recurrence from treatment-related changes. The implementation of these models can facilitate personalized treatment plans and increase the patient’s overall survival or quality of life.

تازه های تحقیق

Mahsa Shakeri (Google Scholar)

Hossein Ghadiri (Google Scholar)

کلیدواژه‌ها
PET؛ Radiomics؛ Glioma؛ Treatment Related Changes؛ Prognosis
مراجع
  1. Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25(12 Suppl 2):iv1-99. doi: 10.1093/neuonc/noad149. PubMed PMID: 37793125. PubMed PMCID: PMC10550277.
  2. Alizadeh M, Broomand Lomer N, Azami M, Khalafi M, Shobeiri P, Arab Bafrani M, Sotoudeh H. Radiomics: The New Promise for Differentiating Progression, Recurrence, Pseudoprogression, and Radionecrosis in Glioma and Glioblastoma Multiforme. Cancers (Basel). 2023;15(18):4429. doi: 10.3390/cancers15184429. PubMed PMID: 37760399. PubMed PMCID: PMC10526457.
  3. Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V, Lombardi G. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Cancers (Basel). 2020;13(1):47. doi: 10.3390/cancers13010047. PubMed PMID: 33375286. PubMed PMCID: PMC7794906.
  4. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amistà P, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol. 2009;27(8):1275-9. doi: 10.1200/JCO.2008.19.4969. PubMed PMID: 19188675.
  5. Drake LR, Hillmer AT, Cai Z. Approaches to PET Imaging of Glioblastoma. 2020;25(3):568. doi: 10.3390/molecules25030568. PubMed PMID: 32012954. PubMed PMCID: PMC7037643.
  6. Kim M, Ladomersky E, Mozny A, Kocherginsky M, O’Shea K, Reinstein ZZ, et al. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021;3(1):1-13. doi: 10.1093/noajnl/vdab125. PubMed PMID: 34647022. PubMed PMCID: PMC8500689.
  7. Jovčevska I, Kočevar N, Komel R. Glioma and glioblastoma - how much do we (not) know? Mol Clin Oncol. 2013;1(6):935-41. doi: 10.3892/mco.2013.172. PubMed PMID: 24649273. PubMed PMCID: PMC3916171.
  8. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020;70(4):299-312. doi: 10.3322/caac.21613. PubMed PMID: 32478924.
  9. Rončević A, Koruga N, Soldo Koruga A, Rončević R, Rotim T, Šimundić T, et al. Personalized Treatment of Glioblastoma: Current State and Future Perspective. 2023;11(6):1579. doi: 10.3390/biomedicines11061579. PubMed PMID: 37371674. PubMed PMCID: PMC10296009.
  10. Santo G, Laudicella R, Linguanti F, Nappi AG, Abenavoli E, Vergura V, et al. The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI. Diagnostics (Basel). 2022;12(4):844. doi: 10.3390/diagnostics12040844. PubMed PMID: 35453892. PubMed PMCID: PMC9027186.
  11. Cui M, Zorrilla-Veloz RI, Hu J, Guan B, Ma X. Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis. Front Neurol. 2021;12:671867. doi: 10.3389/fneur.2021.671867. PubMed PMID: 34093419. PubMed PMCID: PMC8173157.
  12. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, Van Den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9(9):906-20. doi: 10.1016/S1474-4422(10)70181-2. PubMed PMID: 20705518.
  13. Ahrari S, Zaragori T, Rozenblum L, Oster J, Imbert L, Kas A, Verger A. Relevance of Dynamic 18F-DOPA PET Radiomics for Differentiation of High-Grade Glioma Progression from Treatment-Related Changes. 2021;9(12):1924. doi: 10.3390/biomedicines9121924. PubMed PMID: 34944740. PubMed PMCID: PMC8698938.
  14. Albert NL, Galldiks N, Ellingson BM, Van Den Bent MJ, Chang SM, Cicone F, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25(1):e29-41. doi: 10.1016/S1470-2045(23)00525-9. PubMed PMID: 38181810. PubMed PMCID: PMC11787868.
  15. Alongi P, Arnone A, Vultaggio V, Fraternali A, Versari A, Casali C, et al. Artificial Intelligence Analysis Using MRI and PET Imaging in Gliomas: A Narrative Review. Cancers (Basel). 2024;16(2):407. doi: 10.3390/cancers16020407. PubMed PMID: 38254896. PubMed PMCID: PMC10814838.
  16. Bailo M, Pecco N, Callea M, Scifo P, Gagliardi F, Presotto L, et al. Decoding the Heterogeneity of Malignant Gliomas by PET and MRI for Spatial Habitat Analysis of Hypoxia, Perfusion, and Diffusion Imaging: A Preliminary Study. Front Neurosci. 2022;16:885291. doi: 10.3389/fnins.2022.885291. PubMed PMID: 35911979. PubMed PMCID: PMC9326318.
  17. Bonte S, Donche S, Henrotte M, Van Holen R, Goethals I. OS6. 3 Radiomics and machine learning on [18F] FET PET and T1ce MRI discriminate between low-grade and high-grade glioma. Neuro-Oncol. 2018;20(suppl_3):iii226. doi: 10.1093/neuonc/noy139.040.
  18. Bhattacharya K, Rastogi S, Mahajan A. Post-treatment imaging of gliomas: challenging the existing dogmas. Clin Radiol. 2024;79(3):e376-92. doi: 10.1016/j.crad.2023.11.017. PubMed PMID: 38123395.
  19. D’Souza MM, Sharma R, Jaimini A, Panwar P, Saw S, Kaur P, et al. 11C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas. Clin Nucl Med. 2014;39(9):791-8. doi: 10.1097/RLU.0000000000000532. PubMed PMID: 25036022.
  20. Eisazadeh R, Shahbazi-Akbari M, Mirshahvalad SA, Pirich C, Beheshti M. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and Other Less-Commonly Used Radiotracers. Semin Nucl Med. 2024;54(2):293-301. doi: 10.1053/j.semnuclmed.2024.01.002. PubMed PMID: 38331629.
  21. Lohmeier J, Bohner G, Siebert E, Brenner W, Hamm B, Makowski MR. Quantitative biparametric analysis of hybrid 18F-FET PET/MR-neuroimaging for differentiation between treatment response and recurrent glioma. Sci Rep. 2019;9(1):14603. doi: 10.1038/s41598-019-50182-4. PubMed PMID: 31601829. PubMed PMCID: PMC6787240.
  22. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, et al. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol. 2014;16(4):603-9. doi: 10.1093/neuonc/not166. PubMed PMID: 24305722. PubMed PMCID: PMC3956344.
  23. Maurer GD, Brucker DP, Stoffels G, Filipski K, Filss CP, Mottaghy FM, et al. 18F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience. J Nucl Med. 2020;61(4):505-11. doi: 10.2967/jnumed.119.234757. PubMed PMID: 31519802.
  24. Bashir A, Mathilde Jacobsen S, Mølby Henriksen O, Broholm H, Urup T, Grunnet K, et al. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). Neuro Oncol. 2019;21(12):1595-606. doi: 10.1093/neuonc/noz166. PubMed PMID: 31618420. PubMed PMCID: PMC6917428.
  25. Ahrari S, Zaragori T, Zinsz A, Oster J, Imbert L, Verger A. Application of PET imaging delta radiomics for predicting progression-free survival in rare high-grade glioma. Sci Rep. 2024;14(1):3256. doi: 10.1038/s41598-024-53693-x. PubMed PMID: 38332004. PubMed PMCID: PMC10853227.
  26. Barry N, Rowshanfarzad P, Francis RJ, Nowak AK, Ebert MA. Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment. Phys Eng Sci Med. 2021;44(4):1131-40. doi: 10.1007/s13246-021-01049-4. PubMed PMID: 34436751.
  27. Booth TC, Larkin TJ, Yuan Y, Kettunen MI, Dawson SN, Scoffings D, et al. Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma. PLoS One. 2017;12(5):e0176528. doi: 10.1371/journal.pone.0176528. PubMed PMID: 28520730. PubMed PMCID: PMC5435159.
  28. Ehret F, Kaul D, Clusmann H, Delev D, Kernbach JM. Machine Learning-Based Radiomics in Neuro-Oncology. Acta Neurochir Suppl. 2022;134:139-51. doi: 10.1007/978-3-030-85292-4_18. PubMed PMID: 34862538.
  29. Jin W, Fatehi M, Abhishek K, Mallya M, Toyota B, Hamarneh G. Artificial intelligence in glioma imaging: challenges and advances. J Neural Eng. 2020;17(2):021002. doi: 10.1088/1741-2552/ab8131. PubMed PMID: 32191935.
  30. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, De Jong EEC, Van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749-62. doi: 10.1038/nrclinonc.2017.141. PubMed PMID: 28975929.
  31. Kebir S, Schmidt T, Weber M, Lazaridis L, Galldiks N, Langen KJ, et al. A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. Cancers (Basel). 2020;12(11):3080. doi: 10.3390/cancers12113080. PubMed PMID: 33105661. PubMed PMCID: PMC7690380.
  32. Lohmann P, Elahmadawy MA, Gutsche R, Werner JM, Bauer EK, Ceccon G, et al. FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation. Cancers (Basel). 2020;12(12):3835. doi: 10.3390/cancers12123835. PubMed PMID: 33353180. PubMed PMCID: PMC7766151.
  33. Müller M, Winz O, Gutsche R, Leijenaar RTH, Kocher M, Lerche C, et al. Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression. J Neurooncol. 2022;159(3):519-29. doi: 10.1007/s11060-022-04089-2. PubMed PMID: 35852737. PubMed PMCID: PMC9477932.
  34. Carles M, Popp I, Starke MM, Mix M, Urbach H, Schimek-Jasch T, et al. FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation? Radiat Oncol. 2021;16(1):46. doi: 10.1186/s13014-020-01744-8. PubMed PMID: 33658069. PubMed PMCID: PMC7931514.
  35. Paprottka KJ, Kleiner S, Preibisch C, Kofler F, Schmidt-Graf F, Delbridge C, et al. Fully automated analysis combining [18F]-FET-PET and multiparametric MRI including DSC perfusion and APTw imaging: a promising tool for objective evaluation of glioma progression. Eur J Nucl Med Mol Imaging. 2021;48(13):4445-55. doi: 10.1007/s00259-021-05427-8. PubMed PMID: 34173008. PubMed PMCID: PMC8566389.
  36. Li Z, Holzgreve A, Unterrainer LM, Ruf VC, Quach S, Bartos LM, et al. Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma. Eur J Nucl Med Mol Imaging. 2023;50(2):535-45. doi: 10.1007/s00259-022-05988-2. PubMed PMID: 36227357. PubMed PMCID: PMC9816231.
  37. Lohmann P, Kocher M, Ruge MI, Visser-Vandewalle V, Shah NJ, Fink GR, et al. PET/MRI Radiomics in Patients With Brain Metastases. Front Neurol. 2020;11:1. doi: 10.3389/fneur.2020.00001. PubMed PMID: 32116995. PubMed PMCID: PMC7020230.
  38. Hotta M, Minamimoto R, Miwa K. 11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier. Sci Rep. 2019;9(1):15666. doi: 10.1038/s41598-019-52279-2. PubMed PMID: 31666650. PubMed PMCID: PMC6821731.
  39. Mitamura K, Yamamoto Y, Kudomi N, Maeda Y, Norikane T, Miyake K, Nishiyama Y. Intratumoral heterogeneity of 18F-FLT uptake predicts proliferation and survival in patients with newly diagnosed gliomas. Ann Nucl Med. 2017;31(1):46-52. doi: 10.1007/s12149-016-1129-0. PubMed PMID: 27686469.
  40. Shahzadi I, Seidlitz A, Beuthien-Baumann B, Zwanenburg A, Platzek I, Kotzerke J, et al. Radiomics for residual tumour detection and prognosis in newly diagnosed glioblastoma based on postoperative [11C] methionine PET and T1c-w MRI. Sci Rep. 2024;14(1):4576. doi: 10.1038/s41598-024-55092-8. PubMed PMID: 38403632. PubMed PMCID: PMC10894870.
  41. Ari AP, Akkurt BH, Musigmann M, Mammadov O, Blömer DA, Kasap DNG, et al. Pseudoprogression prediction in high grade primary CNS tumors by use of radiomics. Sci Rep. 2022;12(1):5915. doi: 10.1038/s41598-022-09945-9. PubMed PMID: 35396525. PubMed PMCID: PMC8993885.
  42. Jin S, Chen W, Guo X, Xing H, Yang H, Liu Q, et al. A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy. Discov Oncol. 2024;15(1):85. doi: 10.1007/s12672-024-00944-y. PubMed PMID: 38517553. PubMed PMCID: PMC10959905.
  43. Teng C, Zhu Y, Li Y, Dai L, Pan Z, Wanggou S, Li X. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. Front Immunol. 2022;13:899710. doi: 10.3389/fimmu.2022.899710. PubMed PMID: 35677036. PubMed PMCID: PMC9168984.
  44. García-Cabezas S, Rivin Del Campo E, Solivera-Vela J, Palacios-Eito A. Re-irradiation for high-grade gliomas: Has anything changed? World J Clin Oncol. 2021;12(9):767-86. doi: 10.5306/wjco.v12.i9.767. PubMed PMID: 34631441. PubMed PMCID: PMC8479348.
  45. Kirkpatrick JP, Sampson JH. Recurrent malignant gliomas. Semin Radiat Oncol. 2014;24(4):289-98. doi: 10.1016/j.semradonc.2014.06.006. PubMed PMID: 25219814. PubMed PMCID: PMC4522935.
  46. Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol. 1994;30(2):146-9. doi: 10.1016/0167-8140(94)90044-2. PubMed PMID: 8184112.
  47. McDonald MW, Shu HK, Curran WJ Jr, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;79(1):130-6. doi: 10.1016/j.ijrobp.2009.10.048. PubMed PMID: 20399036.
  48. Milano MT, Okunieff P, Donatello RS, Mohile NA, Sul J, Walter KA, Korones DN. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys. 2010;78(4):1147-55. doi: 10.1016/j.ijrobp.2009.09.018. PubMed PMID: 20207495.
  49. Pan H, Alksne J, Mundt AJ, Murphy KT, Cornell M, Kesari S, Lawson JD. Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study. Med Oncol. 2012;29(3):2040-5. doi: 10.1007/s12032-011-0116-5. PubMed PMID: 22108847.
  50. Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol Adv. 2023;5(1):vdad009. doi: 10.1093/noajnl/vdad009. PubMed PMID: 36968288. PubMed PMCID: PMC10034917.
  51. Taylor KR, Barron T, Hui A, Spitzer A, Yalçin B, Ivec AE, et al. Glioma synapses recruit mechanisms of adaptive plasticity. 2023;623(7986):366-74. doi: 10.1038/s41586-023-06678-1. PubMed PMID: 37914930. PubMed PMCID: PMC10632140.
  52. Abbasi AW, Westerlaan HE, Holtman GA, Aden KM, Van Laar PJ, Van Der Hoorn A. Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis. Clin Neuroradiol. 2018;28(3):401-11. doi: 10.1007/s00062-017-0584-x. PubMed PMID: 28466127. PubMed PMCID: PMC6105173.
  53. Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2018;2018:6828396. doi: 10.1155/2018/6828396. PubMed PMID: 30627060. PubMed PMCID: PMC6305027.
  54. Brandsma D, Stalpers L, Taal W, Sminia P, Van Den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6. PubMed PMID: 18452856.
  55. Reddy K, Westerly D, Chen C. MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-grade gliomas. J Med Imaging Radiat Oncol. 2013;57(3):349-55. doi: 10.1111/j.1754-9485.2012.02472.x. PubMed PMID: 23721146.
  56. Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. 2017;14(2):307-20. doi: 10.1007/s13311-016-0507-6. PubMed PMID: 28108885. PubMed PMCID: PMC5398984.
  57. Saidijam M, Afshar S, Ahmad I, Patching S. Nucleoside transporters in PET imaging of proliferating cancer cells using 3ꞌ-deoxy-3ꞌ-[18F] fluoro-L-thymidine. Journal of Diagnostic Imaging in Therapy. 2018;5(1):1-13. doi: 10.17229/jdit.2018-0210-030.
  58. Castelo-Branco M, Moreira A. Combined PET/MRI in brain glioma imaging. In New Insights Into Glioblastoma. Academic Press; 2023. p. 155-65.
  59. Evangelista L, Cuppari L, Bellu L, Bertin D, Caccese M, Reccia P, et al. Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience. Curr Radiopharm. 2019;12(3):220-8. doi: 10.2174/1874471012666190115124536. PubMed PMID: 30644351.
  60. Eertink JJ, Zwezerijnen GJC, Cysouw MCF, Wiegers SE, Pfaehler EAG, Lugtenburg PJ, et al. Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features. Eur J Nucl Med Mol Imaging. 2022;49(13):4642-51. doi: 10.1007/s00259-022-05916-4. PubMed PMID: 35925442. PubMed PMCID: PMC9606052.
  61. Tang C, Ruan R, Xiong Z. Comparison between [18F] FET PET/MRI and [18F] FET PET/CT in the diagnosis of glioma recurrence: a systematic review and meta-analysis. Clin Transl Imaging. 2023;11(5):479-91. doi: 10.1007/s40336-023-00585-1.
  62. Yu P, Wang Y, Su F, Chen Y. Comparing [18F]FET PET and [18F]FDOPA PET for glioma recurrence diagnosis: a systematic review and meta-analysis. Front Oncol. 2024;13:1346951. doi: 10.3389/fonc.2023.1346951. PubMed PMID: 38269019. PubMed PMCID: PMC10805829.
  63. Lohmann P, Lerche C, Stoffels G, Filss CP, Stegmayr C, Neumaier B, et al. P09. 26 FET PET radiomics-diagnosis of pseudoprogression in glioblastoma patients based on textural features. Neuro-Oncology. 2017;19(suppl_3):iii75. doi: 10.1093/neuonc/nox036.282.
  64. Manzarbeitia-Arroba B, Hodolic M, Pichler R, Osipova O, Soriano-Castrejón ÁM, García-Vicente AM. 18F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma. Cancers (Basel). 2023;16(1):195. doi: 10.3390/cancers16010195. PubMed PMID: 38201621. PubMed PMCID: PMC10778283.
  65. Wirsching HG, Roelcke U, Weller J, Hundsberger T, Hottinger AF, Von Moos R, et al. MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clin Cancer Res. 2021;27(1):179-88. doi: 10.1158/1078-0432.CCR-20-2096. PubMed PMID: 32967939.
  66. Seifert R, Kersting D, Rischpler C, Opitz M, Kirchner J, Pabst KM, et al. Clinical Use of PET/MR in Oncology: An Update. Semin Nucl Med. 2022;52(3):356-64. doi: 10.1053/j.semnuclmed.2021.11.012. PubMed PMID: 34980479.
  67. Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007;37(5):316-31. doi: 10.1053/j.semnuclmed.2007.04.001. PubMed PMID: 17707239.
  68. Tabassum M, Suman AA, Suero Molina E, Pan E, Di Ieva A, Liu S. Radiomics and Machine Learning in Brain Tumors and Their Habitat: A Systematic Review. Cancers (Basel). 2023;15(15):3845. doi: 10.3390/cancers15153845. PubMed PMID: 37568660. PubMed PMCID: PMC10417709.
  69. Breiman L. Random forests. Machine Learning. 2001;45:5-32. doi: 10.1023/A:1010933404324.
  70. Rigatti SJ. Random Forest. J Insur Med. 2017;47(1):31-9. doi: 10.17849/insm-47-01-31-39.1. PubMed PMID: 28836909.
  71. Sarica A, Cerasa A, Quattrone A. Random Forest Algorithm for the Classification of Neuroimaging Data in Alzheimer’s Disease: A Systematic Review. Front Aging Neurosci. 2017;9:329. doi: 10.3389/fnagi.2017.00329. PubMed PMID: 29056906. PubMed PMCID: PMC5635046.
  72. Galldiks N, Lohmann P, Cicone F, Langen KJ. FET and FDOPA PET imaging in glioma. In: Glioma Imaging: Physiologic, Metabolic, and Molecular Approaches. Cham: Springer International Publishing; 2019. p. 211-21.
  73. Muthukumar S, Darden J, Crowley J, Witcher M, Kiser J. A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review. Int J Mol Sci. 2022;24(1):408. doi: 10.3390/ijms24010408. PubMed PMID: 36613852. PubMed PMCID: PMC9820099.
  74. Castello A, Castellani M, Florimonte L, Ciccariello G, Mansi L, Lopci E. PET radiotracers in glioma: a review of clinical indications and evidence. Clin Transl Imaging. 2022;10(5):535-51. doi: 10.1007/s40336-022-00523-7.
  75. Gutsche R, Scheins J, Kocher M, Bousabarah K, Fink GR, Shah NJ, et al. Evaluation of FET PET Radiomics Feature Repeatability in Glioma Patients. Cancers (Basel). 2021;13(4):647. doi: 10.3390/cancers13040647. PubMed PMID: 33562803. PubMed PMCID: PMC7915742.
  76. Jiang YQ, Gao Q, Chen H, Shi XX, Wu JB, Chen Y, et al. Positron Emission Tomography-Based Short-Term Efficacy Evaluation and Prediction in Patients With Non-Small Cell Lung Cancer Treated With Hypo-Fractionated Radiotherapy. Front Oncol. 2021;11:590836. doi: 10.3389/fonc.2021.590836. PubMed PMID: 33718144. PubMed PMCID: PMC7947869.
آمار
تعداد مشاهده مقاله: 543
تعداد دریافت فایل اصل مقاله: 1,609


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب